Cannabis is becoming more popular and more available in the United States. It has been approved for use by multiple states for various conditions and several states now allow recreational cannabis. We explore the structure of cannabis distribution, the process of acquisition, outcomes, and the safety of cannabis in the United States.
DonabedianA. Evaluating the quality of medical care. Milbank Q. 1966;44(suppl 3):166-206.
2.
BerwickDFoxDM. “Evaluating the quality of medical care”: donabedian’s classic article 50 years later. Milbank Q. 2016;94(2):237-241.
3.
FujitaKMolesRJChenTF. Quality indicators for responsible use of medicines: a systematic review. BMJ Open. 2018;8(7):e020437.
4.
MainzJ. Developing evidence-based clinical indicators: a state-of-the-art methods primer. Int J Qual Health Care. 2003;15(suppl 1):i5-i11.
5.
McGlynnEA. The outcomes utility index: will outcomes data tell us what we want to know?Int J Qual Health Care. 1998;10(6):485-490.
6.
HaugNAKieschnickDSottileJEBabsonKAVandreyRBonn-MillerMO. Training and practices of cannabis dispensary staff. Cannabis Cannabinoid Res. 2016;1(1):244-251.
7.
MerlinJSAlthouseAFeldmanR, et al.Analysis of state cannabis laws and dispensary staff recommendations to adults purchasing medical cannabis. JAMA Netw Open. 2021;4(9):e2124511.
8.
KadetzP. Manufacturing risk: reframing the discourse of safety of commodified potent substances. J Ethnopharmacol. 2015;167:115-122.
9.
ParveenAParveenBParveenRAhmadS. Challenges and guidelines for clinical trial of herbal drugs. J Pharm BioAllied Sci. 2015;7(4):329-333.
10.
KagenSL. Aspergillus: an inhalable contaminant of marihuana. N Engl J Med. 1981;304(8):483-484.
11.
VerweijPEMeisJF. Microbiological diagnosis of invasive fungal infections in transplant recipients. Transpl Infect Dis. 2000;2(2):80-87.
12.
VerweijPEKerremansJJVossAMeisJF. Fungal contamination of tobacco and marijuana. JAMA. 2000;284(22):2875.
13.
StoneTHenkleJPrakashV. Pulmonary mucormycosis associated with medical marijuana use. Respir Med Case Rep. 2019;26:176-179.
14.
SalamAPPozniakAL. Disseminated aspergillosis in an HIV-positive cannabis user taking steroid treatment. Lancet Infect Dis. 2017;17(8):882.
15.
McKernanKSpanglerJZhangL, et al.Cannabis microbiome sequencing reveals several mycotoxic fungi native to dispensary grade Cannabis flowers. F1000Res. 2015;4:1422.
16.
RuchlemerRAmit-KohnMRavehDHanusL. Inhaled medicinal cannabis and the immunocompromised patient. Support Care Cancer. 2015;23(3):819-822.
17.
CesconDWPageAVRichardsonSMooreMJBoernerSGoldWL. Invasive pulmonary aspergillosis associated with marijuana use in a man with colorectal cancer. J Clin Oncol. 2008;26(13):2214-2215.
18.
HamadehRArdehaliALocksleyRMYorkMK. Fatal aspergillosis associated with smoking contaminated marijuana, in a marrow transplant recipient. Chest. 1988;94(2):432-433.
19.
KurupVPResnickAKagenSLCohenSHFinkJN. Allergenic fungi and actinomycetes in smoking materials and their health implications. Mycopathologia. 1983;82(1):61-64.
JerushalmiSMaymonMDombrovskyAFreemanS. Fungal pathogens affecting the production and quality of medical cannabis in Israel. Plants (Basel). 2020;9(7):882.
22.
BradyKT. Medical Marijuana: putting the cart before the horse. Am J Psychiatry. 2020;177(7):570-571.
23.
Bonn-MillerMOLoflinMJEThomasBFMarcuJPHykeTVandreyR. Labeling accuracy of cannabidiol extracts sold online. JAMA. 2017;318(17):1708-1709.
24.
RiceASCBeltonJArendt NielsenL. Presenting the outputs of the IASP Presidential Task Force on Cannabis and Cannabinoid Analgesia. Pain. 2021;162(suppl 1):S3-S4.
25.
HaroutounianSGilronIBeltonJ, et al.Societal issues and policy implications related to the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. Pain. 2021;162(suppl 1):S110-S116.
26.
InnocenziEDe DomenicoECiccaroneF, et al.Paternal activation of CB2 cannabinoid receptor impairs placental and embryonic growth via an epigenetic mechanism. Sci Rep. 2019;9(1):17034.
27.
McCleanDKZimmermanAM. Action of delta 9-tetrahydrocannabinol on cell division and macromolecular synthesis in division-synchronized protozoa. Pharmacology. 1976;14(4):307-321.
28.
HenrichRTNogawaTMorishimaA. In vitro induction of segregational errors of chromosomes by natural cannabinoids in normal human lymphocytes. Environ Mutagen. 1980;2(2):139-147.
29.
MorishimaA. Effects of cannabis and natural cannabinoids on chromosomes and ova. NIDA Res Monogr. 1984;44:25-45.
30.
du PlessisSSAgarwalASyriacA. Marijuana, phytocannabinoids, the endocannabinoid system, and male fertility. J Assist Reprod Genet. 2015;32(11):1575-1588.
31.
ZimmermanAMZimmermanSRajAY. Effects of cannabinoids on spermatogenesis in mice. Adv Biosci. 1978;22-23:407-418.
32.
BadawyZSChohanKRWhyteDAPenefskyHSBrownOMSouidAK. Cannabinoids inhibit the respiration of human sperm. Fertil Steril. 2009;91(6):2471-2476.
33.
ReeceASHulseGK. Epidemiological overview of multidimensional chromosomal and genome toxicity of cannabis exposure in congenital anomalies and cancer development. Sci Rep. 2021;11(1):13892.
34.
SheikhanNYPintoAMNowakDA, et al.Compliance with cannabis act regulations regarding online promotion among canadian commercial cannabis-licensed firms. JAMA Netw Open. 2021;4(7):e2116551.
35.
AbuhasiraRShbiroLLandschaftY. Medical use of cannabis and cannabinoids containing products - Regulations in Europe and North America. Eur J Intern Med. 2018;49:2-6.
36.
LancasterKSeearKRitterA. Making medicine; producing pleasure: a critical examination of medicinal cannabis policy and law in Victoria, Australia. Int J Drug Policy. 2017;49:117-125.
37.
LeknesSBernaCLeeMCSnyderGDBieleGTraceyI. The importance of context: when relative relief renders pain pleasant. Pain. 2013;154(3):402-410.
38.
OgborneACSmartRGAdlafEM. Self-reported medical use of marijuana: a survey of the general population. CMAJ (Can Med Assoc J). 2000;162(12):1685-1686.
39.
CostiniukCTSaneeiZSalahuddinS, et al.Cannabis consumption in people living with HIV: reasons for use, secondary effects, and opportunities for health education. Cannabis Cannabinoid Res. 2019;4(3):204-213.
40.
KvammeSLPedersenMMRomer ThomsenKThylstrupB. Exploring the use of cannabis as a substitute for prescription drugs in a convenience sample. Harm Reduct J. 2021;18(1):72.
41.
WeissSRBHowlettKDBalerRD. Building smart cannabis policy from the science up. Int J Drug Policy. 2017;42:39-49.
42.
ZyllaDMEklundJGilmoreG, et al.A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction. Support Care Cancer. 2021;29(12):7471-7478.
43.
BolandEGBennettMIAllgarVBolandJW. Cannabinoids for adult cancer-related pain: systematic review and meta-analysis. BMJ Support Palliat Care. 2020;10(1):14-24.
44.
CitromeLKetterTA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67(5):407-411.
45.
HauserWWelschPKlosePRadbruchLFitzcharlesMA. Efficacy, tolerability and safety of cannabis-based medicines for cancer pain: a systematic review with meta-analysis of randomised controlled trials. Schmerz. 2019;33(5):424-436.
46.
MuckeMPhillipsTRadbruchLPetzkeFHauserW. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3:CD012182.
47.
StockingsECampbellGHallWD, et al.Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018;159(10):1932-1954.
48.
FisherEMooreRAFogartyAE, et al.Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain. 2021;162(suppl 1):S45-S66.
49.
MooreRAFisherEFinnDP, et al.Cannabinoids, cannabis, and cannabis-based medicines for pain management: an overview of systematic reviews. Pain. 2021;162(suppl 1):S67-S79.
50.
HaroutounianSArendt-NielsenLBeltonJ, et al.International association for the study of pain presidential task force on cannabis and cannabinoid analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. Pain. 2021;162(suppl 1):S117-S124.
51.
BachhuberMASalonerBCunninghamCOBarryCL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med. 2014;174(10):1668-1673.
52.
BradfordACBradfordWDAbrahamABagwell AdamsG. Association between US state medical cannabis laws and opioid prescribing in the medicare part D population. JAMA Intern Med. 2018;178(5):667-672.
53.
HsuGKovacsB. Association between county level cannabis dispensary counts and opioid related mortality rates in the United States: panel data study. BMJ. 2021;372:m4957.
54.
ShahAHayesCJLakkadMMartinBC. Impact of medical marijuana legalization on opioid use, chronic opioid use, and high-risk opioid use. J Gen Intern Med. 2019;34(8):1419-1426.
55.
LiangDBaoYWallaceMGrantIShiY. Medical cannabis legalization and opioid prescriptions: evidence on US Medicaid enrollees during 1993-2014. Addiction. 2018;113(11):2060-2070.
56.
LivingstonMDBarnettTEDelcherCWagenaarAC. Recreational cannabis legalization and opioid-related deaths in Colorado, 2000-2015. Am J Public Health. 2017;107(11):1827-1829.
57.
ChihuriSLiG. State marijuana laws and opioid overdose mortality. Inj Epidemiol. 2019;6:38.
58.
KimJHMartinsSSShmulewitzDHasinD. Association between fatal opioid overdose and state medical cannabis laws in US national survey data, 2000-2011. Int J Drug Policy. 2022;99:103449.
59.
HasinDSShmulewitzDCerdaM, et al.U.S. adults with pain, a group increasingly vulnerable to nonmedical cannabis use and cannabis use disorder: 2001-2002 and 2012-2013. Am J Psychiatry. 2020;177(7):611-618.
60.
SeguraLEMauroCMLevyNS, et al.Association of US medical marijuana laws with nonmedical prescription opioid use and prescription opioid use disorder. JAMA Netw Open. 2019;2(7):e197216.
61.
OlfsonMWallMMLiuSMBlancoC. Cannabis use and risk of prescription opioid use disorder in the United States. Am J Psychiatry. 2018;175(1):47-53.
62.
ShoverCLDavisCSGordonSCHumphreysK. Association between medical cannabis laws and opioid overdose mortality has reversed over time. Proc Natl Acad Sci U S A. 2019;116(26):12624-12626.
63.
LichtmanAHLuxEAMcQuadeR, et al.Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manag. 2018;55(2):179-188.e171.
64.
JohnsonJRBurnell-NugentMLossignolDGanae-MotanEDPottsRFallonMT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manag. 2010;39(2):167-179.
65.
PortenoyRKGanae-MotanEDAllendeS, et al.Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438-449.
66.
FallonMTAlbert LuxEMcQuadeR, et al.Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. Br J Pain. 2017;11(3):119-133.
67.
ReisfieldGMWasanADJamisonRN. The prevalence and significance of cannabis use in patients prescribed chronic opioid therapy: a review of the extant literature. Pain Med. 2009;10(8):1434-1441.
68.
McCartyD. Does medical cannabis reduce use of prescription opioids?Am J Psychiatry. 2018;175(1):6-7.
69.
ImtiazSElton-MarshallTRehmJ. Cannabis liberalisation and the US opioid crisis. BMJ. 2021;372:n163.
70.
VoelkerR. States move to substitute opioids with medical marijuana to quell epidemic. JAMA. 2018;320(23):2408-2410.
71.
EstebanJGimenoCBarrilJAragonesAClimentJMde la Cruz PellinM. Survival study of opioid addicts in relation to its adherence to methadone maintenance treatment. Drug Alcohol Depend. 2003;70(2):193-200.
72.
BegleyCGIoannidisJP. Reproducibility in science: improving the standard for basic and preclinical research. Circ Res. 2015;116(1):116-126.
73.
IoannidisJP. Why most published research findings are false. PLoS Med. 2005;2(8):e124.
74.
HillAB. The environment and disease: association or causation?Proc R Soc Med. 1965;58:295-300.
75.
BirdA. The epistemological function of Hill's criteria. Prev Med. 2011;53(4-5):242-245.
76.
DunnKEBergeriaCLHuhnAS, et al.Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model. Neuropsychopharmacology. 2021;46(8):1451-1459.
NarangSWasanADRossELMichnaEChenJYJamisonRN. Patients with chronic pain on opioid therapy taking dronabinol: incidence of false negatives using radioimmunoassay. J Opioid Manag. 2008;4(1):21-26.
79.
SeelingWKneerLBucheleB, et al.[Delta(9)-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain]. Anaesthesist. 2006;55(4):391-400.
80.
HumphreysKSaitzR. Should physicians recommend replacing opioids with Cannabis?JAMA. 2019;321(7):639-640.
81.
NooriAMiroshnychenkoAShergillY, et al.Opioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studies. BMJ Open. 2021;11(7):e047717.
82.
BabalonisSLofwallMRSloanPANuzzoPAFanucchiLCWalshSL. Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans. Psychopharmacology (Berl). 2019;236(11):3341-3352.
83.
SihotaASmithBKAhmedSA, et al.Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control. Int J Clin Pract. 2021;75(8):e13871.
84.
CerdaMMauroCHamiltonA, et al.Association between recreational marijuana legalization in the United States and changes in marijuana use and cannabis use disorder from 2008 to 2016. JAMA Psychiatr. 2020;77(2):165-171.
85.
BlancoCHasinDSWallMM, et al.Cannabis use and risk of psychiatric disorders: prospective evidence from a US National longitudinal study. JAMA Psychiatr. 2016;73(4):388-395.
86.
FreemanTP. Potent questions about cannabis and mental health. Lancet Psychiatr. 2015;2(3):195-196.
87.
FreemanTPWinstockAR. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med. 2015;45(15):3181-3189.
88.
Lipperman-KredaSGrubeJW. Impacts of Marijuana commercialization on adolescents’ marijuana beliefs, use, and co-use with other substances. J Adolesc Health. 2018;63(1):5-6.
89.
ShiYCumminsSEZhuSH. Medical marijuana availability, price, and product variety, and adolescents’ marijuana use. J Adolesc Health. 2018;63(1):88-93.
90.
LlewellynGCO’RearCE. Examination of fungal growth and aflatoxin production on marihuana. Mycopathologia. 1977;62(2):109-112.
91.
ChusidMJGelfandJANutterCFauciAS. Letter: pulmonary aspergillosis, inhalation of contaminated marijuana smoke, chronic granulomatous disease. Ann Intern Med. 1975;82(5):682-683.
92.
BenedictKThompsonGR3rdJacksonBR. Cannabis use and fungal infections in a commercially insured population, United States, 2016. Emerg Infect Dis. 2020;26(6):1308-1310.
93.
VerweijPEHowardSJMelchersWJDenningDW. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat. 2009;12(6):141-147.
94.
TahaTMeiriDTalhamySWollnerMPeerABar-SelaG. Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies. Oncologist. 2019;24(4):549-554.
95.
Bar-SelaGCohenICampisi-PintoS, et al.Cannabis consumption used by cancer patients during immunotherapy correlates with poor clinical outcome. Cancers (Basel). 2020;12(9):2447.
96.
HsiaoPClavijoRI. Adverse effects of cannabis on male reproduction. Eur Urol Focus. 2018;4(3):324-328.
97.
TilakSKZimmermanAM. Effects of cannabinoids on macromolecular synthesis in isolated spermatogenic cells. Pharmacology. 1984;29(6):343-350.
98.
ReeceASHulseGK. Impacts of cannabinoid epigenetics on human development: reflections on Murphy et. al. ‘cannabinoid exposure and altered DNA methylation in rat and human sperm’ epigenetics 2018; 13: 1208-1221. Epigenetics. 2019;14(11):1041-1056.
99.
MurphySKItchon-RamosNViscoZ, et al.Cannabinoid exposure and altered DNA methylation in rat and human sperm. Epigenetics. 2018;13(12):1208-1221.
100.
BlakeEARossMIhenachoU, et al.Non-prescription cannabis use for symptom management amongst women with gynecologic malignancies. Gynecol Oncol Rep. 2019;30:100497.
101.
ReeceASHulseGK. A geospatiotemporal and causal inference epidemiological exploration of substance and cannabinoid exposure as drivers of rising US pediatric cancer rates. BMC Cancer. 2021;21(1):197.
102.
ReeceASHulseGK. Contemporary epidemiology of rising atrial septal defect trends across USA 1991-2016: a combined ecological geospatiotemporal and causal inferential study. BMC Pediatr. 2020;20(1):539.
103.
ReeceASHulseGK. Broad Spectrum epidemiological contribution of cannabis and other substances to the teratological profile of northern New South Wales: geospatial and causal inference analysis. BMC Pharmacol Toxicol. 2020;21(1):75.
104.
ReeceASHulseGK. Co-occurrence across time and space of drug- and cannabinoid- exposure and adverse mental health outcomes in the National Survey of Drug Use and Health: combined geotemporospatial and causal inference analysis. BMC Publ Health. 2020;20(1):1655.
105.
ReeceASHulseGK. Canadian cannabis consumption and patterns of congenital anomalies: an ecological geospatial analysis. J Addict Med. 2020;14(5):e195-e210.
106.
ReeceASHulseGK. Cannabis consumption patterns explain the East-West gradient in Canadian neural tube defect incidence: an ecological study. Glob Pediatr Health. 2019;6:2333794X19894798.
107.
ReeceASHulseGK. Cannabis teratology explains current patterns of coloradan congenital defects: the contribution of increased cannabinoid exposure to rising teratological trends. Clin Pediatr (Phila). 2019;58(10):1085-1123.
108.
ReeceASNormanAHulseGK. Cannabis exposure as an interactive cardiovascular risk factor and accelerant of organismal ageing: a longitudinal study. BMJ Open. 2016;6(11):e011891.
109.
ReeceASHulseGK. Chromothripsis and epigenomics complete causality criteria for cannabis- and addiction-connected carcinogenicity, congenital toxicity and heritable genotoxicity. Mutat Res. 2016;789:15-25.
110.
ReeceASHulseGK. Quadruple convergence - rising cannabis prevalence, intensity, concentration and use disorder treatment. Lancet Reg Health Eur. 2021;10:100245.
111.
ReeceASHulseGK. Causal inference multiple imputation investigation of the impact of cannabinoids and other substances on ethnic differentials in US testicular cancer incidence. BMC Pharmacol Toxicol. 2021;22(1):40.
112.
ReeceASHulseGK. Cannabinoid exposure as a major driver of pediatric acute lymphoid Leukaemia rates across the USA: combined geospatial, multiple imputation and causal inference study. BMC Cancer. 2021;21(1):984.
113.
ShoverCLHumphreysK. Six policy lessons relevant to cannabis legalization. Am J Drug Alcohol Abuse. 2019;45(6):698-706.
114.
BalonR. The madness of medical marijuana and marijuana legalization. Ann Clin Psychiatry. 2016;28(4):229-230.
115.
AyersJWCaputiTLLeasEC. The need for federal regulation of marijuana marketing. JAMA. 2019;321(22):2163-2164.
116.
VothEA. Guidelines for prescribing medical marijuana. West J Med. 2001;175(5):305-306.
117.
BostwickJM. Blurred boundaries: the therapeutics and politics of medical marijuana. Mayo Clin Proc. 2012;87(2):172-186.
118.
GrotenhermenF. Cannabinoids. Curr Drug Targets - CNS Neurol Disord. 2005;4(5):507-530.
119.
RamirezRLJerniganDH. Increasing alcohol taxes: analysis of case studies from Illinois, Maryland, and Massachusetts. J Stud Alcohol Drugs. 2017;78(5):763-770.
120.
ElderRWLawrenceBFergusonA, et al.The effectiveness of tax policy interventions for reducing excessive alcohol consumption and related harms. Am J Prev Med. 2010;38(2):217-229.
121.
AggarwalSKCarterGTSullivanMDZumBrunnenCMorrillRMayerJD. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag. 2009;5(3):153-168.
